Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Non-Current Assets (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Other Non-Current Assets for 13 consecutive years, with $33000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 28.26% year-over-year to $33000.0; the TTM value through Mar 2026 reached $33000.0, down 28.26%, while the annual FY2025 figure was $46000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets hit $33000.0 in Q1 2026 for Viking Therapeutics, down from $46000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $46000.0 in Q3 2024 and bottomed at $33000.0 in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $37588.2, with a median of $33000.0 recorded in 2022.
  • Year-over-year, Other Non-Current Assets surged 39.39% in 2024 and then decreased 28.26% in 2026.
  • Viking Therapeutics' Other Non-Current Assets stood at $33000.0 in 2022, then changed by 0.0% to $33000.0 in 2023, then surged by 39.39% to $46000.0 in 2024, then changed by 0.0% to $46000.0 in 2025, then dropped by 28.26% to $33000.0 in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $33000.0, $46000.0, and $46000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.